New Drug: Dostarlimab for advanced dMMR endometrial cancer
|New Drug: Dostarlimab for advanced dMMR endometrial cancer|
Annals of Oncology (2020) 31 (suppl_4): S1142-S1215.
Oaknin A, et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNEThttps://doi.org/10.1016/annonc/annonc325
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.